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1.1 COLORECTAL LIVER METASTASIS AND THE EVOLUTION OF 
SURGICAL RESECTABILITY CRITERIA 
 
Colorectal cancer is the third most common cancer[1]. Up to 70% of patients develop 
distant metastases during the progress of the disease, most commonly located in the 
liver; in 30–40% of these patients, the metastatic spread is confined to the liver[2]. 
Without treatment, the median survival of colorectal liver metastases (CRLM) is 6–8 
months[3].  
Hepatic resection is the only treatment modality associated with long-term survival in 
patients with CRLM, with 5-year survival rates ranging from 40 to 58% in selected 
patients[4]. The surgical management of CRLM has changed dramatically during the 
past three decades, leading to a marked improvement in overall survival, with a near 
doubling of the historical 5-year survival rate of 30% to 35%, in parallel with advances 
in surgical technique, better perioperative care, as well as more effective systemic 
chemotherapeutic agents[5].  
Historically, major hepatectomy represented the treatment of choice in patients with 
CRLM. This paradigm has changed with the diffusion of the parenchymal-sparing liver 
resections (PSLR). Therefore, there has been an expansion in the criteria of resectability 
for colorectal liver metastasis and specifically, the number of metastasis, size of tumor 
lesion, and a mandatory 1 cm margin of resection are no longer considered absolute 
criteria for a curative surgical approach. The current definition of resectability includes 
the potential for complete resection with tumor-free margins (R0 resection), with 
preservation of at least two disease-free liver segments with viable vascular in-flow, 
outflow, and biliary drainage and an adequate future liver remnant (FLR) volume[6], 
that means at least 20% of the total estimated liver volume for normal parenchyma, 
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30%–60% if the liver is injured by chemotherapy, steatosis, or hepatitis, or 40%–70% in 
the presence of cirrhosis, depending on the degree of underlying hepatic dysfunction[7].  
Nowadays, unresectable extrahepatic metastases or unresectable primary tumor, 
prohibitive anesthesiological risk, and medical contraindications to hepatectomy still 
constitute contraindications for resection. 
Indeed, resection of the hepatic lesion should only be considered, however, when the 
extra-hepatic metastasis is surgically resectable or controllable via adjuvant therapies[8]. 
Nowadays, a greater number of parenchymal sparing strategies are being performed, 
which are considered by many the first-choice strategy because it preserves non-tumoral 
parenchyma, allows repeated resection in case of recurrence, and does not compromise 
oncological outcomes[9-11]. Indeed, parenchymal sparing resections might be 
particularly beneficial for patients with a high operative risk for major resection, who 
would otherwise not be candidates for resection. Intraoperative ultrasound (IOUS) has a 
key role in the modern hepatic surgery not only to better stage the disease, but above all 
as guidance to resection, as it is able to confirm and extend previous findings. The 
extensive use of IOUS allows to maximize the parenchymal sparing of healthy liver 
tissue, becoming essential for intraoperative decision-making[12].  
However nearly 80% of patients with CRLM are not to be resectable at the time of 
diagnosis[13, 14]. These patients were traditionally considered for palliative 
chemotherapy. The advent of more effective chemotherapy and developments of 
surgical procedure and perioperative management have expanded the pool of resectable 
patients with CRLM, and a certain number of patients with initially unresectable CRLM 
can be converted to resectable[15, 16]. However, even with effective chemotherapy with 
or without targeted therapy, conversion rate is reported to be only 20%[16].  
For patients with extensive bilateral multinodular CRLM, a single hepatectomy, even 
with specific procedures such as portal vein embolization (PVE) and local ablation 
therapy is sometimes not sufficient to remove all the tumors, even after significant 
downsizing by chemotherapy. In these cases, it is necessary to balance two conflicting 
6 
 
objectives: (1) to achieve a complete tumor resection with curative intent (negative 
margins), and (2) to preserve as much liver parenchyma as possible to avoid liver 
failure. However, major hepatectomies are often required to achieve an R0 resection, 
and these are associated with substantial rates of morbidity and mortality[17]. Post-
hepatectomy liver failure (PHLF) is the main cause of death after major hepatectomy 
and it is strictly related to the volume and quality of the future liver remnant (FLR)[18]. 
Several strategies have been developed in order to minimize the risk of PHLF and 
expand resectability. 
So, in 2000, Adam et al. reported the concept of two-stage hepatectomy (TSH), based on 
two sequential procedures to remove multiple bilateral tumors impossible to remove by 
a single hepatectomy, and using the liver regeneration obtained after the first 
procedure[19]. 
Twelve years after the introduction of TSH, Schnizbauer et al.[20] reported a technical 
innovation to this important concept that undoubtedly represented a major breakthrough 
in surgery. This new approach, so-called associating liver partition and portal vein 
ligation for staged hepatectomy (ALPPS), considerably accelerates FLR hypertrophy 
and drastically reduces the time interval between stages, therefore increasing 
resectability rates. As originally described, the technique consists in right PVL combined 
with in-situ splitting of liver parenchyma during the first stage, followed 7–10 days after 









1.2 THE PARADIGM SHIFT FROM LARGE TO PARENCHYMAL SPARING 
RESECTIONS AND THE IMPORTANCE OF THE SURGICAL MARGIN  
 
Surgeons have progressively moved from the “1-cm” rule to the “1-mm” rule in the 
treatment of CRLM and a negative (≥ 1-mm) surgical margin is the present standard 
(Figure 1). 
 
Figure 1. The paradigm shift from large to parenchymal sparing resections. 
 
In the 1985, Cady et al. have reported that a surgical margin less than 1 cm was 
associated with a significantly shorter disease-free survival (DFS). As a result, major 
centers have adopted a 1-cm margin as a target during resection to minimize hepatic 
recurrence and improve survival after resection of CRLM. In fact, a 1-cm margin has 
been proposed as the minimally acceptable margin even for ablative techniques[21].  
Later on, considering that the use of 1-cm rule for resection could exclude a large 
number of patients from the only therapeutic interventions able to affect long term 
survival, not reaching this margin became not a contraindication but a strong 
recommendation[22]. In 1998, firstly Elias stated that the “one-centimeter free margin” 
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concept should not be rigidly adhered to. For the author, it is justifiable to undertake 
resection of liver metastases from colorectal cancer, provided it is curative and safe, 
even in the face of what would classically be considered poor prognostic factors. 
In 2011, Holdhoff evaluated the resection margin through a combination of 
histopathologic and genetic analyses and found that tumors with a significant radiologic 
response to chemotherapy were not associated with any increase in mutant tumor DNA 
in beyond 4 mm of the main tumor, supporting the clinical evidence that a negative (R0) 
margin may be sufficient. Furthermore, authors did not find evidence of residual tumor 
DNA in the region in which the tumor likely existed prior to chemotherapy, suggesting 
that tumors which respond to chemotherapy likely do so in a concentric fashion[23]. 
In the last 15 years, various authors have shown comparable results with narrower 
margins and even with positive microscopic margins (R1). In 2002, Kokudo et al. 
reported that micrometastases around liver tumors were mostly confined to the 
immediate vicinity of the tumor border and so hypothesized that the minimum surgical 
margin for successful liver resection without cut-end recurrence may lie somewhere 
between 0 mm and 10 mm. Indeed, a surgical margin of 2 mm appears to be a clinically 
acceptable minimum requirement, carrying an approximately 6% risk of margin-related 
recurrence. Kokudo’s study represents the first multicenter report to examine the effect 
of surgical margin status after resection of hepatic CRM on both margin recurrence and 
survival[24]. 
In 2005, for the first time in literature, according to Pawlik et al., a positive margin was 
considered to be a margin less than 1 mm, defining as the presence of exposed tumor 
along the line of transection or the presence of tumor cells at the line of transection 
detected by histologic examination. Although a positive surgical margin was associated 
with an increased risk of margin recurrence (11%), the width of the margin was not 
significant. Patients with a margin of 1 mm to 4 mm did have a slightly increased rate of 
margin recurrence compared with patients who had wider margins; this did not reach 
statistical significance. In conclusion, this study demonstrated that the width of a 
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negative surgical margin does not affect survival, recurrence risk, or site of 
recurrence[25]. 
Similarly, detachment of CRLM from major intrahepatic vessels if they have not been 
infiltrated (R1 vascular resection) was recently shown to have an excellent outcome. In 
fact, in 2016, Viganò et al. tried to clarify the clinical relevance of R1 resection for 
CRLMs in a large, recent, single-center series, with a focus on the distinction between 
tumor exposure along the transection plane (standard R1) and CRLM detachment from 
intrahepatic vessels that is called R1 vascular (R1Vas) (Figure 2). Instead of R1 
parenchymal (R1Par), representing an independent negative prognostic factor of overall 
survival, conversely R1vascular surgery achieves outcomes equivalent to R0 resection. 
So, CRLM detachment from intrahepatic vessels can be pursued to increase patient 
resectability and resection safety[26]. 
 
R1PAR: R1 parenchymal; R1VAS: R1 vascular 
Figure 2. Representation of the different types of section margins 
In conclusion, after Pawlik’study, the paradigm shift from large to parenchymal sparing 
resections had really achieved, leading to a modification of the oncological concept of 
safe resection margins.  
Because the current consensus is that the thickness of the margin does not modify 
survival, the aggressive indications for CRLM and complexity of surgical procedures 
corresponded to high R1 resection rates. In the most experienced hepatobiliary units, R1 
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resection occurs in 10 to 30%[27] of patients, reaching 30 to 60% of patients with 
multiple bilobar CRLM or with initially unresectable disease[28].  
However, the adequate width of the surgical margin is still a matter of debate, as the 
outcomes of R1 resection is associated with higher local recurrence rate and worse 
survival and several pathological data support the inadequacy of R1 surgery.  
Actually, in 2008, Adam et al. first reported no negative prognostic impact of positive 
surgical margins. Some recent studies have shown that perioperative chemotherapy may 
reduce or even cancel the relevance of R1 surgery[29]. 
Later on, subsequent several recent studies had denied any negative prognostic role of 
R1 resection in the era of aggressive and effective perioperative chemotherapy[30, 31].  
Finally, in 2015, the EGOSLIM (Expert Group on OncoSurgery management of Liver 
Metastases) group convened and published a brief but clear statement; ‘‘safe resection 
margins are still a goal of therapy; a minimal surgical clearance margin of 1 mm has 
been suggested as sufficient.’’ Nonetheless, the optimal surgical margin for CRLM 
remains unknown[32].  
Considering that several evidences is still in favor of R0 surgery, a reappraisal of R1 










1.3 RECURRENCE AFTER LIVER RESECTION FOR COLORECTAL LIVER 
METASTASIS 
 
Advances in surgical and medical oncology have resulted in prolongation of survival for 
patients with colorectal liver metastasis. However, many patients still develop recurrent 
disease. Studies addressing overall recurrence have reported rates ranging from 60 to 
85% at one year[33, 34]. Specifically, hepatic recurrence occurs in 50% of patients 
during follow-up, with 2.8% to 13.9% presenting with surgical margin recurrence[33, 
34].  
However, data on rates and patterns of recurrence following curative intent surgery for 
colorectal liver metastasis are limited. In fact, most studies reporting on outcomes 
following surgical management of colorectal metastasis have exclusively focused on 
overall survival rather than recurrence[33]. Unfortunately, to date, most series on the 
topic of pattern of recurrence for colorectal metastasis have been limited by small 
sample sizes and the few largely single-institution studies were published in an era prior 
to more effective systemic chemotherapy. 
One of the most frequently used scoring systems is the clinical risk score (CRS) 
developed by Fong et al.[33]. This system categorizes patients into “low risk” and “high 
risk” groups for disease recurrence, with low scoring patients having an overall median 
survival of 74 months and high-scoring patients having an overall median survival of 22 
months. CRS was calculated as 1 point per criterion met: node positive primary, >1 
preoperative liver lesion, largest preoperative liver lesion >5 cm, preoperative CEA 
>200 pg/L, and time between removal of primary and appearance of liver metastases 
<12 months. Since a clinical risk score of this kind was important for the accurate care 
of colorectal cancer patients, after its publication in 1999, the CRS has seen 
longstanding and pervasive use in surgical practice. Nevertheless, the improvements in 
clinical care may have modified the accuracy of this scoring system and probably, today 
it would be necessary to reassess and modernize the score, adding some factors now 
relevant for the management of CRLM and that may improve the prognostic power of 
the CRS in the modern era of liver resection[35]. 
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For example, blood loss and need for a transfusion remain a significant concern that can 
impact both immediate and long-term outcomes. Allogeneic red blood cell transfusions 
and their transfusion-related immunomodulation effects have been recently suggested as 
a cause for early cancer recurrence and worse overall outcomes[36].  
Then, numerous intra-operative strategies have been developed to limit blood loss. Of 
these, portal pedicle clamping (PPC), first described by Hogarth Pringle for liver trauma, 
is one of the only strategies proven effective to reduce intra-operative blood loss in 
randomized controlled trials. Portal pedicle clamping has also been recently employed in 
regular hepatobiliary practice and its effects on survival and recurrence has been 
investigated. De Carlis et al. found that patients who received intermittent hepatic 
pedicle clamping, comparing with those who did not, had similar 5-year overall survival 
rate, but the 5-year recurrence-free rate was significantly higher. Noteworthy, the study 
was limited by the exclusion of patients with higher-risk disease according to CRS[37]. 
Conversely, other results are consistent with the lack of a difference in overall survival 
and recurrence-free survival[38]. 
 
Moreover, in the last decade numerous studies have investigated factors associated with 
recurrence after hepatectomy in CRLM (Table 1).  
Several clinicopathologic and morphological factors are now considered to be 
independent prognostic factors associated with recurrence and hepatic recurrence. 
Primary colorectal tumor stage, differentiation and lymph node metastasis of primary 
colorectal tumor, time interval to the appearance of metastasis, number and size of 
metastases, preoperative CEA level, neoadjuvant/adjuvant chemotherapy and the status 
of the resection margin have been established as important determinants of tumor 
recurrence in CRLM[30, 34, 36, 39-50].  
Among these several prognostic factors for recurrence, the surgical margin status or 
resection margins (RMs) is a technical, operative variable that is directly dependent 
upon the surgeon’s technique and it has also been traditionally associated with long-term 
prognosis[51]. However, as previously mentioned, the importance of the surgical margin 
achieved during liver resection, as prognostic factor to predict the development of local 
recurrence and long-term outcome, remains controversial.  
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Table 1. Factors associated with recurrence after hepatic surgery for colorectal liver metastasis. Literature 
between 2012 -2018. 
 
Authors N Median 
age 
[years] 
Type of study Median 
FU 
[months] 








279 65.5 Perspective 6 (univariate) 
Poorly differentiate CRC, synchronous metastasis, ≥5 cm of liver 
mass, preoperative CEA≥50 ng/mL, positive liver resection margin, 
and surgery alone without perioperative chemotherapy 
(multivariate) 
poorly differentiated CRC, ≥5-cm metastatic tumor size, positive liver 





206 62 Retrospective 29 (univariate) 
Tumor size CEA pre-op, margin status 
(multivariate) 




2320 63 Retrospective 27 Node-positive primary, No. of lesions>3, Size of largest lesion>4 cm Overall 
Intrahepatic 
Extrahepatic 















34.4 T3–4 primary tumor; synchronous CRLM; > 3 CRLM; 0 mm margin 
liver resection; associated intraoperative radiofrequency ablation 










264 62 Retrospective 34 T stage primary tumor; positive lymph node in primary tumor; >4 
CRLM; no neoadjuvant chemotherapy 
 













243 66 Retrospective 58 For liver recurrence: male sex and advanced primary tumors (Dukes C) 
For any recurrence: Number of metastases, largest tumor size  










253 66 Prospective and 
retrospective 
60 RMs do not impact hepatic recurrence, whereas extrahepatic 










255 56 Retrospective 28.6 CEA ≥ 30 ng/ml, primary tumor lymph vascular invasion (LVI), 







846 61 Retrospective 24 (Univariate) 
Age, primary tumor stage, bilobar distribution of liver metastases, 
preoperative chemotherapy cycles and lines, response to last-line 
chemotherapy, tumor number and size at hepatectomy, CEA and 
CA19-9 at hepatectomy, PVE, major hepatectomy, two-step approach, 
surgical margin status of liver metastases, and concomitant 
extrahepatic disease  
(Multivariate) 
Age ≤57 years, preoperative chemotherapy line, progression 
of disease during last-line chemotherapy, 3 tumors at hepatectomy, and 




307 57.5 Retrospective 31.7 (Univariate) 
Node-positive primary tumor and metastatic diameter > 3 cm 
(Multivariate) 


























1669 61 Retrospective 30 (Univariate) 
Node-positive primary tumor, synchronous hepatic metastasis, history 
of RFA, and receipt of chemotherapy, the clinical risk score, tumor 
size >5, preoperative CEA level, surgical margin status were not 
associated 
(Multivariate) 
rectal primary tumor site, disease-free interval >12 months, history of 




intra hepatic + 
lung 


























159 58.5 Retrospective 38.5 (Univariate) 
Centrally located metastasis, primary tumor in the transverse colon, 
metastasis in regional lymph nodes, initial extrahepatic metastasis, 
synchronous liver metastasis, multiple lesions, poorly differentiated 
tumor, and resection margin <10 mm  
(Multivariate) 









70 ≥ 53 y 
49% 
Retrospective NA (Univariate) 
Age >53 years, advanced T stage of primary tumor, moderately- poorly 
differentiated tumor, positive and narrow resection margin, 
preoperative CEA level >30 ng/ml, DFS <18 months 
(Multivariate) 
Perioperative chemotherapy and achievement of resection margins 
beyond 1 mm 
 NA 
Abbreviations: SMR Surgical margin recurrence; ER: early recurrence (within 6 months after liver resection; * within 
8 months after liver resection); CEA carcinoembryonic antigen level; CRC colorectal cancer; CRLM colorectal liver 
metastasis; RFA radiofrequency ablation; NA not available. 
 
 
Actually, the prolonged overall survival observed with submillimeter margins is likely a 
microscopic surrogate for the biologic behavior of a tumor rather than the result of 
surgical technique[53]. In fact, the potential aggressiveness of colorectal cancer is 
readily evident when relapses occur early after resection of the primary tumor, when it 
recurs in the liver with large or bilobar metastases, and when there is little or no 
measurable response to chemotherapy[54, 55].  
Indeed, in 2006 Takahashi et al. showed that time to recurrence after liver resection for 
CRLM strongly correlated with prognosis and especially patients with disease 
recurrence within 6 months after liver resection have the poorest outcome[56]. 
According to these data, early recurrence was defined as any recurrence occurring within 
6 months after liver resection and the same time interval was adopted by Malik et al. in 
their study about early recurrences after liver resection for CRLM[57]. Interestingly, in 
this study the author found that the presence of eight or more metastases was the only 
significant predictor of early disease recurrence on multivariable analysis. In addition, 
the presence of numerous hepatic metastases was also a predictor of extra-hepatic 
recurrences and unresectable recurrent disease, suggesting that early recurrence is a 
marker of aggressive tumor biology[57]. 
In 2004, Tanaka et al. had already reported that short tumor doubling time in CRLM is a 
poor prognostic factor for both overall and DFS[55]. The authors demonstrated that only 
doubling time was retained as independent predictive factors for remnant liver 
recurrence and a doubling time of 45 days or less was associated with multiple, early 
remnant liver recurrences, precluding repeat hepatectomy and resulting in a poor 
prognosis. Interestingly, only tumor size and the prognostic nutritional index (PNI) 
based on the peripheral blood lymphocyte count and serum albumin concentration were 
significantly related to tumor doubling time, suggesting how doubling time would be 
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determined by the interplay of both tumor characteristics and the patients’ immune and 
nutritional status. 
Nowadays, indicators of tumor biology and how they might influence outcome are of 
increasing interest. Mutation of the KRAS gene may be an indicator of biological 
aggressiveness. In this perspective, Cucchetti1et al. stratified a cohort of patients who 
underwent resection for only metachronous disease in three subgroup according to a 
mathematical model to estimate CRLM doubling times: the fast-growing CRLMs, 
doubling time less than 48 days; the intermediate-growing CRLMs, doubling time 48–82 
days and the slow-growing CRLMs, doubling time more than 82 days. The study 
demonstrated that the tumor doubling time was shorter in patients with more advanced 
primary tumor stages, with mutant KRAS and in those who did not receive 
chemotherapy. In addition, for the fast-growing group, the risk of recurrence was highest 
within the first postoperative year and was about 7 per cent per month[54]. 
Several studies had showed that histopathologic factors of primary CRC were related to 
liver metastasis. Conversely, few studies, focusing on the histopathology of metastatic 
lesions as a predictive marker of tumor recurrence have been performed. 
Histopathological studies of liver metastases have resulted in the description of three 
histological growth pattern (GP). These are: desmoplastic GP, where a rim of collagen 
surrounds the tumor tissue and separates the liver parenchyma from the cancer cells; 
pushing GP, where tumor cells push the liver parenchyma aside, encompassing pressure 
on the hepatocytes at the tumor margin; and replacement GP, where tumor cells replace 
the hepatocytes hereby maintaining the trabecular architecture of the liver parenchyma 
(Figure 3)[58]. CRLMs grow according to different GPs with different angiogenic 
properties. In a recent study that enrolled 205 patients from 1995 to 2005, who were 
resected for liver metastasis and followed for 2 years, a pushing GP was the only 
independent predictor of poor survival, suggesting that this pattern is characterized by a 
more aggressive tumor biology in comparison to patients with desmoplastic or 
replacement GP[59]. Similarly, in a second prognostic study by Nielsen et al., survival 
was related to GPs, and desmoplastic growth was associated with small tumor size, 
dense lymphocytic infiltration and a more favorable prognosis in term of overall 
survival[60]. A more recent study considered also the effect of the therapeutic approach, 
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comparing chemo-naive patients and patients receiving neo-adjuvant therapy[58]. 
Authors found that desmoplastic GP in resected liver metastases predicts a reduced risk 
of recurrence in comparison to other GPs, while the patients resected for pushing 
metastases tended to have earlier recurrence. Interestingly, the prevalence and impact of 




Figure. 3 Illustration of growth patterns in colorectal liver metastases. The different growth 
patterns are illustrated in a, b, g (desmoplastic growth pattern), b, e, h (pushing growth pattern) and 
c, f, i (replacement growth pattern). The mixed growth pattern is not shown, but is usually a mixture 
of two patterns, often including a pushing component[58]. 
 
 
Finally, data on the prognostic implications of vascular, biliary, perineural and 
lymphatic invasion in patients with CRLM are limited. Gomez et al, identified three 
independent predictors of DFS, mainly tumor number, perineural invasion, and resection 
margin. In addition, the presence of perineural invasion was the only independent 
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predictor of poorer overall survival on multivariate analysis[47]. More recently, Park et 
al. found that tumor infiltrating inflammation and presence of dedifferentiation of 
metastatic lesion were independent risk factors for tumor recurrence after hepatic 
resection in CRLM[61]. 
In other words, the pathophysiological mechanisms behind overall and hepatic 
recurrence may not simplistically include inadequate margin resection, but rather they 
could represent the expression of cancer aggressiveness and the natural progression of 
micrometastatic disease from the primary tumor.  
Further elucidation of the mechanisms and biological pathways involved in and 
responsible for the differences in GP between CRC liver metastases in different patients 
might lead to therapeutic agents and strategies and may contribute to a histology-based 
prognostic biomarker for patients with colorectal liver metastases. 
Therefore, the relationship between the growth rate of CRLMs and biological features of 
colorectal cancer may provide additional information related to outcome pathologic 
prognostic markers of hepatic tumors predicting the prognosis of these patients have 






















2.  THE STUDY  
 
 
2.1 AIMS OF THE STUDY  
The aim of this study was to investigate the impact of margin width resection on early 
liver recurrence and DFS after hepatic resection for colorectal metastasis in a 
consecutive series of patients from a single institution. The hypothesis of the present 
study was that margin width resection (R0 or R1) does not influence oncological 
outcomes after resection for CRLM.  
In addition, the study aimed to identify other clinicopathologic prognostic factors 
predictors for early recurrence (defined as recurrence within 6 months of CRLM 
resection) and for DFS. 
Moreover, the study sought to examine the pattern of early and late recurrence (intra- or 
extra-hepatic recurrence) of patients who were managed with curative intent resection. 
 
2.2 MATERIALS AND METHODS 
 
2.2.1 STUDY DESIGN AND PATIENTS’ SELECTION  
This is a prospective observational study, performed at the Oncological Surgery, 
Hospital Policlinic San Martino, Genoa, Italy from 1st April 2014 to the 1st June 2019. 
The study was approved by the Local Ethical Committee and met the guidelines of the 
local Govern-mental Agency. Patients provided written informed consent before 
inclusion. 
Patients undergoing primary hepatic resection for colorectal liver metastasis with 
curative intent and having a minimum follow-up period of 6 months were included.   
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The selection criteria for surgery in our center included a sufficient remaining tumor-
free liver volume[6, 7] with adequate blood perfusion and bile drainage, and absence of: 
a) non-resectable extrahepatic metastases, and/or b) no disseminated disease as 
evaluated pre-operatively.  
Exclusion criteria for this study were patients who underwent repeat hepatic resections, 
who colorectal resection was not performed in our center, patients with R2 resections or 
Dindo-Clavien V and patients who underwent combined resection with radiofrequency 
ablation (RFA). 
 
2.2.2 PREOPERATIVE EVALUATION  
Before surgery, all patients were evaluated with a baseline history and physical 
examination, serum laboratory tests, and appropriate imaging studies. Preoperative 
investigations included computed tomography (CT) scan of the chest and 
abdomen/pelvis, and tumour marker analysis (CEA: carcinoembryonal antigen). In cases 
with an inconclusive CT scan, magnetic resonance imaging (MRI) of the liver, contrast-
enhanced ultrasound and 18 F-fluorodeoxyglucose 18(FDG)-positron emission 
tomography (PET)/CT scan were performed.  
Each patient was discussed in a multidisciplinary team meeting with surgeons, 
oncologists and radiologists and also geriatric evaluation in patients 65-year-old and 
older.  
Preoperative chemotherapy was administered for patients with initially unresectable 
CRLM in the conversion setting or patients with synchronous (diagnosed before, during, 
or within 3 months after colorectal resection) or marginally resectable CRLM in the 
neoadjuvant setting. 
Standard demographic and clinicopathologic data were collected for each patient 
including sex, age, ASA score, CEA level, comorbidity (with particular attention to 
chronic liver disease and cirrhosis, staging through MELD and Child-Pugh Score), as 
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well as treatment related variables including history of preoperative chemotherapy, 
number of cycles.  
Data were also collected on primary tumor characteristics, specifically on primary tumor 
location, date of resection (primary), TNM stage, genotype mutations (KRAS, NRAS, 
BRAF), microsatellite instability. Furthermore, the Lymph nodes ratio (LNR), defined 
as the ratio between positive lymph nodes and the total number of retrieved lymph 
nodes, was also collected for each colorectal surgical procedure. Then, date of detection 
of CLM and presentation (synchronous vs. metachronous), number, size and location of 
CLM were recorded. In the present study, diagnosis of liver metastasis within three 
months were considered as metachronous, even though up-to-date there is no consensus 
on the defining time point for synchronous/metachronous disease[62]. 
 
2.2.3 SURGICAL PROCEDURES  
All patients underwent conventional open liver resection with curative intent, and to 
achieve complete resection (R0) while preserving as much normal functional liver 
parenchyma (with adequate vascular inflow, outflow, and biliary drainage) as possible. 
Resection of three or more segments was considered a major hepatic resection. The 
presence of extrahepatic tumors was not considered a contraindication to hepatic 
resection if the lesions were limited and resectable. Extrahepatic disease identified in the 
abdominal cavity was resected at the same time as hepatic resection. For extrahepatic 
disease located outside the abdomen, resection was performed 2–3 months after 
hepatectomy if the disease remained controlled with interval chemotherapy.  
The operations were performed by two different surgeons. Intraoperative ultrasound of 
the liver was carried out in all patients. A central venous pressure less than 5 mm Hg 
was maintained during parenchymal transection and monitored by central venous access. 
All patients received therapeutic liver resection and hepatic hilar lymph node dissection 
was not performed routinely. Anatomical resection was characterized as complete 
anatomical resection based on Couinaud’s classification (segmentectomy, 
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sectionectomy, and hemihepatectomy or extended hemihepatectomy) in patients with an 
acceptable liver reserve[63]. Non-anatomical resection (atypical resection) was the first-
choice type of resection, according to the concept of parenchyma spearing, but if it is not 
suitable, a two-stage hemihepatectomy approach, as ALPPS, has been performed. As 
regard synchronous metastases, primary tumor resection was combined to metastases 
resection balancing patient's clinical conditions and fitness for surgery and the burden 
and extension of metastatic disease. 
Pringle maneuver had always been carried out. Intermittent portal pedicle clamping was 
used at the discretion of the operating surgeon (no longer than 15 minutes clamped with 
5 minutes unclamped).  
In general, the hepatic parenchymal transection was performed through the clamp-crush 
technique. Once the parenchyma is crushed, the exposed vessels and bile ducts were 
divided through absorbable suture or non-absorbable suture ligation. Alternatively, 
vascular clips for larger caliber vessels and bipolar energy device (bipolar forceps or 
Aquamantys®) for smaller caliber vessels were used.  
When hemostasis on the liver section area is not convincing, a flap of sealant matrix of 
human fibrinogen/human thrombin is applied. 
As regarding resection margins (RM), RM <1 mm were defined as positive (R1), in 
accordance with Pawlik et al[25]. In addition, RM status was obtained from the 
microscopic measurements in the histological reports, in which the closest distance was 
measured between the tumor edge and the transection surface of the liver parenchyma. 
Microscopically and  in line with the histological reports, the widths were stratified as 
coincidental margins if the tumor was in contact with the surgical margin (0 mm); 






2.2.4 POSTOPERATIVE PERIOD AND FOLLOW-UP  
Postoperative complications were graded according to the validated classification 
criteria described by Dindo Clavien Classification[64] and the Comprehensive 
Complication Index (CCI®-Calculator)[65] and major complications were defined as 
any complication of grade III or higher.  
Adjuvant chemotherapy was recommended routinely, using the same protocol as that 
applied before surgery.  
All patients were followed up every three months for the first two years, with a physical 
examination, carcinoembryonic antigen (CEA) measurement, and abdominal 
ultrasonography. Every six months, patients underwent computed tomography scan of 
the abdominal/thoracic/pelvic region (enhanced MRI could replace CT) to detect any 
intrahepatic or distant recurrence. In accordance with previous reports[56, 57], early 
recurrence was defined as any recurrence (liver recurrence (LR) or extrahepatic 
recurrence) occurring within 6 months after liver resection. 
Patient characteristics and details of surgical treatment, as margin resection width, and 
perioperative chemotherapy were analyzed to identify predictive factors of early 
recurrence.  
At last date of follow-up date overall survival (OS) and DFS were also collected.  
 
2.2.5 STATISTICAL ANALYSIS 
Patients’ data were collected from a prospective computerized database. The descriptive 
analysis for quantitative variables was expressed as median or mean and standard 
deviation (SD).  
The association between categorical data was performed with the two-tailed Pearson χ2, 
or Fisher’s exact test when appropriate. Student’s t-test was used to analyze any 
significant clinical pathological differences among patients who developed early 
recurrence when compared to the remaining cohort.  
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Recurrence and DFS were estimated using the Kaplan-Meier method, and any 
significant difference between the sub-groups noted by univariate analysis was 
compared using the log-rank test. 
All statistical analyses were performed using the SPSS for Windows version 20.0 (SPSS 






















2.3.1. PATIENTS’ DEMOGRAPHICS AND CLINICAL CHARACTERISTICS  
During the study period, 61 patients underwent primary hepatic resection for CRLM. 
Two patients died postoperatively within 30 days. Nine patients were excluded due to 
uncompleted collection data. Thus, a total of 50 patients were ultimately included in the 
study (Figure 4). 
 
ER Early recurrence; LR liver recurrence; ExR extra-hepatic recurrence 




There were 34 (68%) men and 16 (32%) women, and the median age at the time of 
surgery was 70 (range 38 to 86); 18 patients (35% of the sample) were age 75 or older. 
More than 82% of patients had one or more comorbidities and 50% of patients had 
multimorbidity (i.e. CRLM plus two or more comorbidities), with a median number of 
drugs of 4. The most common comorbidities were diabetes, hypertension, heart failure 
and COPD. So, that most of patients were classified as ASA 3 (38%) or ASA 2 (42%). 
Patients’ clinical characteristics are illustrated in Table 1. 
 
Table 1. Patients’ demographic and clinical characteristics. 
VARIABLES N % 






















NUMBER OF DRUGS Median (range) 4 (0-9) 
COMORBIDITY 
Diabetes   
Hypertension  
Heart failure  
































MELD (N=42) Median (range)             7 (6-20) 
MARKERS 
CEA > 200 g/L 








 pre-operative  
 Adjuvant  










Overall, 18 patients (36%) underwent neoadjuvant chemotherapy before liver surgery, 
including 83% who received neo-adjuvant fluoropyrimidine-based cytotoxic 
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chemotherapy. In detail, 8 patients received neo-adjuvant 5FU ± oxaliplatin; 5 patients 
neo-adjuvant 5FU ± oxaliplatin + bevacizumab or + panitumumab (n=2). Only a 
minority of the patients (n = 3) received fluoropyrimidine-based treatment ± irinotecan ± 
cetuximab (EGFR inhibitor). Then, biologic agents such as bevacizumab, cetuximab, 
and panitumumab were used in 9 patients (50%).  Preoperative chemotherapy included ≥ 
4 cycles in all 18 patients (100 %) while ≥ 6 cycles in 13 (72%) patients. 
 
2.3.2 CLINICOPATHOLOGIC CHARACTERISTICS OF THE PRIMARY 
AND METASTATIC TUMORS 
Table 2 illustrates primary and metastatic tumor characters. With respect to primary 
colorectal cancer characteristics, almost 54% of the sample had a primary colon tumor, 
while 46% had a primary rectal tumor. In terms of pathologic stage, most patients had 
T3–T4 tumors (n = 48; 96%), lymph node metastasis (n = 28; 56%). During the primary 
resection, the median number of lymph nodes removed per patient was 20 (range: 9–55). 
Thirty-three patients (69%) had moderately differentiated colorectal tumors (G2), while 
8 (16%) poorly differentiated tumors (G3 e 4).  
In 36 patients were available the genotype analysis of KRAS and BRAF mutation. 
KRAS and BRAF mutations were detected in 30.5% and 0.5% of the cases, respectively. 
Indeed, all patients reported microsatellite stability (MSS). 
In 33 patients (66%), the presentation of liver metastasis was synchronous with the 
primary while 17 patients (34%) had metachronous liver metastasis with a median 
disease-free time of 11 months. 
The median number of liver metastasis was 1 (range 1 to 10). Sixty-three per cent of 
patients had a solitary liver tumor, while 19 patients (37%) had ≥ 2 tumors and 73% of 
patients had tumors measuring <5 cm.  
27 
 
Most patients had bilobar hepatic disease (68%) while six patients confined to only one 
hemi-liver (32%). Indeed, the most prevalent growth pattern distribution were the 
pushing GP (39%), the mixed GP (39%) and the replacement (18%). 
 
Table 2. Clinicopathologic characteristics of the primary and metastatic tumors 
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2.3.3 SURGICAL RESECTIONS AND POSTOPERATIVE RESULTS 
Surgical treatment was conventional open liver resection with curative intent in all 
patient. The distribution of type of hepatic resections is shown in Table 3.  
Patients undergoing combined surgery were 16 (32%), one patient was submitted to 
staged liver resections and underwent portal vein embolization. The most common 
surgical resections performed in this series were single and multiple wedge resection, 
counting for the almost 80% of the total procedures.  
The blood transfusions were made only in two cases during surgery, while during the 
postoperative period seven patients were treated with antiplatelet agents. 
The Pringle maneuver was used in all patients, and when needed, the median of time of 
application was 38 min (5-80 min). 
The median length of hospital stay was 9 days (range 6 to 27). Intensive care admission 
after surgery was needed in 13 (26%) patients, but only for the first 24 hours.  
As regarding resection margins, the mean resection margin in all patients was 1.4 mm ± 
1.5 mm, which reflects a parenchyma-sparing operative approach. Margin status was 
unknown only in one patient. The distribution of RMs, defined as positive (R1) if ≤ 1 
mm according to Pawlik et al.[25] was represented in Figure 5. An R0 resection was 
achieved in in 23 (47%) patients and an R1 resection occurred in the remaining 26 
(53%) patients. Histological reports categorized 24% patients as coincidental margins (0 
mm); 40% with margins greater than 0.1 mm to 1 mm; 36% with margins greater than 1 
mm; and no patients with margins greater than 1 cm. 
 
Table 3. Types of surgery and resection margin status. 
SURGERY N % 
Segmentectomy 
Single wedge resection 
Multiple wedge resection 
Subsegmentectomy 
Hemihepatectomy 



















 intestinal resections 
 abdominal wall surgery 
 stoma closure 
 































IBL Median (range) [ml] 125 (15-800) 
MARGIN STATUS (N=49) 
0 mm 
0 - 1 mm 









OPERATING TIME MEDIAN (range) [min] 
Liver section time Median [min] 
162 (55-345) 
50 (10-120) 
HOSPITAL STAY Median (renge) [day] 9 (6-75) 
Abbreviations: CRC colorectal cancer; IBL intra-operative blood loss 
 
 
Abbreviations: R: resection; * according to Pawlik[25]. 
Figure 5. Histograms of distribution of margin resection width that were recorded in pathology reports.  
Within 30 days of surgery, 36 patients (72%) developed ≥1 medical or surgical 
complication, either during the hospitalization or after discharge, without leading to 
readmission (Table 4). The most common complications were minor (50%), or even 
classified as I -II grade according to Dindo-Clavien classification[64]. Actually, 







0 mm 0,5 mm 1 mm 2 mm 3 mm 4 mm 6 mm
R1 *
R0 * 
Coincidental R  
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hemorrhage, bile leak and liver insufficiency, these complications were uncommon and 
only 22% were major complication (> III grade). Bile leak and abscess at the resection 
site were the most frequent (8% and 6% respectively) and they required to be treated 
with percutaneous drainage placement. Reoperation occurred in three cases but as 
complication related to colorectal surgery (2 patients who developed anastomotic leak 
and one patient whit obstruction bowel). Indeed, no bleeding occurred in this series and 
the median perioperative blood loss was 100 ml (15-800). Nevertheless, most 
complications in this series were pulmonary (14%) and renal (18%). 
Although there seemed to be an increased length of hospital stay in parallel with the 
degree of severity of the complications according to Dindo-Calvien classification 
(Figure 6), these difference did not reach the statistically significance (no complications 
8.4 days; I-II grade 10.6 days and III-IV grade 13.3 days; p<0.2). 
The distribution of complicated patients according to Comprehensive Complication 
Index (CCI) is shown in Figure 7, in which each complication grade is designated to 
prefixed scores (grade I = 8.7, grade II = 20.9, grade IIIa = 26.2, grade IIIb = 33.7, grade 
IVa = 42.4, grade IVb = 46.2). As the majority of grade I and grade II complicated 
patients showed a single complication, the median CCI was 12.2 (range 0-62.9). Indeed, 
high CCI scores were positively correlated with prolonged hospital stay (Pearson 
correlation t = 2.15, df = 36, p-value <0.03; 95%CI: 0.02 - 0.59; cor 0.33) (Figure 8). 
Table 4.  Incidence and severity of all postoperative complications. 
 N of patients 
[n=50 (%)] 




















Comprehensive complication index (CCI) 12.2 (0-62.9) 












































Perioperative blood loss [ml] 100 (15-800) 
HOSPITAL STAY Median (range) [days]  9 (6-75) 





















2.3.4 DISEASE RECURRENCE AND OVERALL SURVIVAL. 
The overall median follow-up period in this study sample was 23 months (range: 2-70 
months).  
At the end of the follow-up, as of January 2020, 34 (68%) patients were alive, of which 
21 (61%) disease-free. Sixteen (32%) patients died, of which 6 (37,5%) died of 
cardiovascular causes while 10 patients reported cancer related death. In these letter 
cases, the mean DFS and OS were 13 ± 8 months and 25 ± 17 months, respectively. 
During the follow up period, recurrence after liver resection was documented in 24 
patients (48%) (Appendix A). Recurrence rate within the first year was 38% (19 
patients) (Figure 9), and only 2 recurrences were found after the second year from liver 
surgery. One-year and two-year mortality were 12% and 22%, respectively. 
 
Figure 9. Distribution of rate of recurrence during the follow up period. 
Early recurrence (within 6 months after liver resection) occurred in 11 patients (22% of 
the sample and 46% of the total recurrences), including 4 patients (36%) with liver-only 
recurrence and 7 patients (63%) with systemic recurrence (with or without liver 





















There was no difference in hepatic recurrences in the early recurrence group than in the 
late recurrence group (50% vs. 50%; p =0.8), neither in extra-hepatic recurrences. 
 
 
Figure 10. Pattern of early and late recurrence. 
 
2.3.5 FACTORS ASSOCIATED TO EARLY RECURRENCE AND DISEASE-
FREE SURVIVAL: UNIVARIATE ANALYSIS 
Clinical characteristics of the involved patients and results of the performed univariate 
analysis of registered clinical factors are shown in Table 5. According to univariate 
analysis, no significant differences were found in early recurrence and DFS between 
gender, location of the primary tumor, number and size of resected liver metastases, 
growth pattern and KRAS wild type.  
Time of diagnosis of liver metastases was the only significant prognostic factor for both 
DFS and for early recurrence. 
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Moreover, histological grade of primary tumor (G2:33% vs. G3:86% vs. G4:100%; 
p<0.040) and synchronous presentation of liver metastases (80% vs. 20%; p<0.037) 
were associated with shorter DFS. 
There was a slightly significant association between the severity of postoperative 
complication and the occurrence of a recurrence disease (p<0.08; Table 5). Indeed, 
patients who developed severe postoperative complications (grade III and IV Dindo-
Clavien) reported a mean DFS of 479 days versus 312 days in the subgroup of patients 
who had complication grade I-II (p<0.06) (Figure 11). 
Table 5. Univariate analysis of prognostic factors on early recurrence and DFS. 
Parameter DFS 
[n (%)] 







































































































































Surgical margin stratified in mm 
0 mm 
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Abbreviation: CRS Clinical Risk Score (Fong et al.[33])  
Note: *according to Pawlik[25]; **Dindo Clavien classification[64]. 
 
 
Figure 11. Distribution of mean DFS in days stratified by postoperative complication according to Dindo-
Clavien Classification (A) and boxplot comparing group of patients with Dindo-Clavien I-II and with 




Patients with a resection margin of ≥1 mm presented shorter DFS compared with those 
with margin < 1 mm, with median survival of 13 months and 16 months, respectively. 
However, there was no statistically significant difference between the R0 and R1 groups 
and even between the stratification of surgical margin size in relation to the DFS and 
early recurrence. Indeed, patients with wider-margin groups showed similar trend of 
recurrence in comparison with the narrow-margin group. This is confirmed by the 
overlapping Kaplan–Meier curves demonstrated in Figure 12 A and B. 
 
 
Figure 12.  Kaplan-Meier curve comparing early recurrence (A) and DFS (B) after resection of colorectal 










Liver resection, combined with modern chemotherapy, is considered the standard 
treatment for patients with resectable CRLM. Along with the advances in perioperative 
care, resectability and the overall survival of the patients with colorectal liver metastasis 
have shown remarkable improvements. However, the recurrence of hepatic metastasis 
after liver resection remains a concern worldwide.  
An increasing number of complex resections are performed in which the extent of 
hepatic involvement frequently mandates close resection margins. Nevertheless, the 
prognostic significance of margin status still remains unclear, mainly in the relationship 
with the risk of early recurrence. Therefore, the optimal margin width represents a 
challenging issue in hepatic surgery. 
In this study, we presented data from a single-center experience on hepatic resection of 
colorectal metastases with a minimum follow up of 6 months and an average 23 months. 
Early recurrence rates were reported at about 21% in a previous large-scale study[50] 
and our cohort of patients showed similar early recurrence rates (22%). Conversely, 
other reports described excellent outcomes, as in Jung’s study in which early recurrence 
occurred in 10,8% patients[34] or in the LiverMetSurvey in the 10,6%[43]. Anyway, 
recurrence after resection remains a common event after liver resection. In fact, recently 
Imai found that in patients who received preoperative chemotherapy, early recurrence ( 
within 8 months) reached the 45% and age, number of preoperative chemotherapy lines, 
response to last-line chemotherapy, number of tumors, and CA19-9 at hepatectomy were 
identified as independent predictive factors for early recurrence[44]. 
These different results in recurrence rate may be due to the clinical and methodological 
heterogeneity of the published studies, in term of single institution enrollment, small 
sample size, exclusion/inclusion of patients with extrahepatic disease and different span 
time of follow up. Moreover, the cutoff value used to define early recurrence varied in 
different series, ranging from 4 months to 18 months[40, 42, 44]. However, in the 
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present study early recurrence was defined as a relapsed disease within 6 months, which 
is the most commonly adopted definition [56, 57]. 
In the present study, several clinical, pathological, and surgical factors have been tested 
for correlation with early recurrence and DFS in univariate analyses with a specific 
focus on the impact of resection margin depth.  
Time of diagnosis of liver metastases was the only significant factor related to early 
recurrence, whereas only two variables showed significant relevance in the occurrence 
of DFS. In details, patients with poorly differentiate tumor and synchronous metastasis 
tended to have disease recurrence compared to patients with G1-2 or metachronous 
lesions. These results were in accordance with previous report[50], suggesting that the 
difference in prognosis was not merely related to the time of detection in the disease 
progress, but synchronous metastasis might represent a more disseminated disease, 
compared to metachronous metastasis. This tendency to spread, leading to earlier 
recurrence and worse prognosis, could encourage to give more intense follow-up and 
adjuvant chemotherapy after liver resection in the synchronous group of patients[66]. 
Furthermore, there was no significant difference in recurrence disease according to the 
three different histological patterns of the tumour-liver interface of CRC liver 
metastases, termed pushing, replacement and desmoplastic growth pattern. This feature 
was in contrast with previous studies [58-60] but probably the lack of consistency was 
due to the high prevalence in our sample of the pushing and mixed growth pattern. 
The present study examined also the impact of postoperative morbidity, establishing that 
patients who experienced a complication had an increased risk of recurrence. Mainly, 
the severity of the complication correlated with outcome as patients with more severe 
complications (grade III and IV) had the worse DFS.  
The overall morbidity rate in the present study was not consistent with other previous 
series, in which complication rate is lower, about 22%[67] or 30%[68]. The high rate of 
complications was probably due to the peculiar phenotype of enrolled patients, 
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characterized by older adults with a median age 70.5 years and with several 
comorbidities and associated polypharmacy (with a mean number of drugs of 4). 
Interestingly, the median age of the present study was almost ten years higher than the 
current reports in the field of colorectal liver metastasis surgery.  
Anyway, even though the elevated overall postoperative morbidity, our series reported a 
median CCI of 12.2, describing complications of very modest severity. In other term, 
they corresponded to two complications of grade I, which were probably related to organ 
dysfunction secondary to patient’s premorbid conditions.  
Differently from Dindo-Clavien Classification, in the present study CCI positive 
correlated with the length of stay. In fact, while Dindo-Clavien grading is based only on 
the most severe forms of complications and ignores other minor complications, the key 
feature of the CCI is the mathematical summation of all complications, displaying a 
continuous figure from 0 (no complications) to 100 (death)[65], that measured the 
overall magnitude of all complications. In line of these considerations, the continuous 
monitoring of the CCI can mirror surgical performance and provide feedback to the 
surgeon.  
Few previous studies examined the association between the severity of complications 
and short-term and long-term outcomes, rarely focusing on DFS and reporting 
conflicting results. The current study supported the notion of reduced DFS in patient 
who had severe postoperative complications. It has been hypothesized that major 
abdominal surgery initiates a systemic inflammatory response characterized by raised 
levels of inflammatory cytokines such as interleukin. Complications may further 
perpetuate an inflammatory response, thereby maintaining a state of 
immunosuppression, that promote cancer growth and may be responsible for such poor 
prognosis.[67]. In particular, severe infectious complications like septicemia lead to an 
extended period of immunosuppression, which allows residual tumor cells to further 
proliferate and survive in the host[69]. Indeed, patients who experience postoperative 
complications might be unable to undergo postoperative chemotherapy. 
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In line with that a preoperative optimization, meticulous surgical technique and careful 
management in the postoperative period became a key issue in CRLM surgery, able to 
reduce the incidence of complications and influencing long-term outcomes.  
As regard the main objective of this study, no significant differences were found in the 
early recurrence rates and disease-free survival in R1 versus R0 patients. Indeed, no 
significant difference was found between coincidental margins (0 mm) or wider margins 
with regard to DFS and to early recurrence (Table 5). So, the study supports the concept 
that the width of cancer-free resection margin is not important in modern liver resection 
practice, showing that 1-mm margin is sufficient for cure of patients with resectable 
CRLM.  
About twenty years ago, important studies overwhelmed the historical concept that 1.0-
cm margin was not an absolute requirement for a curative approach in the treatment of 
patients with colorectal cancer liver metastases. In the early 2000s both Kokudo et al. 
and Pawlik et al. found that even 2-5 mm and 1-4 mm is enough to improve survival[24, 
25]. In 2008 Haas et al. were one of the first to publish a follow-up study including 
nearly 500 CRLM resected patients and suggested that the survival of patients who had 
R1 resection was similar to those who underwent R0 resection, despite a higher 
recurrence rate[29]. Whereas several authors agree that R1 resection is associated with a 
higher local recurrence risk[29, 70, 71], other studies stated that R1 margin status was 
not associated with survival after controlling for competing risk factors[72]. 
Bodingbauer et al. found that the sub-centimeter surgical margins were not an 
independent risk factor for recurrence[73].  
These controversies regarding the optimal width of surgical margins indicate that other 
biological factors could be involved in the physiopathology of recurrence. The 
development of recurrence and life expectancy after liver resection depend on the 
complex interaction between the tumor biology of the primary colorectal cancer, 
treatments’ plan and patient response. Cucchetti et al. observed a significant relationship 
between doubling time in the primary tumor and CRLM growth rate. Mainly, the fast-
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growing tumors, that showed a peak for recurrence within the first year after surgery up 
to 7%, represented a form of aggressive colorectal cancers that may have already seeded 
in the liver and other organs. Of outmost importance, this aggressiveness is maintained 
after hepatectomy and might account for high rates of early recurrence[54].  
Indeed, if an R1 margin was simply due to surgical failure, the risk for recurrence should 
be high early after surgery and then decrease over time. Instead, it remained consistently 
above that for R0 margins, suggesting that an R1 margin reflects a more advanced tumor 
burden with higher metastatic potential over the entire postoperative time period[54]. 
Similarly, in the present study, the lack of association between R1 status and DFS or 
early recurrence disease suggested that R1 margin status may be a surrogate indicator of 
advanced and/or more extensive disease. Even exploratory in nature, the present study 
demonstrated that tumor biology (in term of grading and synchronous metastasis) rather 
than R1 resection was associated recurrence disease. As such, the negative impact of R1 
status on DFS may not derive from the leaving of microscopic tumor cells at the surgical 
margin, but, rather, from the more aggressive biological phenotype that makes 
extirpation of the tumor with negative surgical margins more difficult. 
Surgical resection of colorectal liver metastases should nowadays be focused on the 
recurrence-free survival time rather than the overall survival time, as it is known that in 
the era of efficient chemotherapy the long-term outcome benefit conferred by R0 
resection disappeared. Up to date, the risk of an R1 resection should not be considered a 
contraindication to surgery with curative intent, as neoadjuvant chemotherapy may 
destroy peripheral micrometastases before liver resection, minimizing consequently the 
residual micro-metastatic disease[74]. In line with that, Ayez and colleagues supported 
that the correlation between the width of the surgical margin and survival was only 
applicable in patients who did not receive preoperative chemotherapy[30]. 
Even exploratory in nature, the strengths of the present study are its prospective nature, 
the choice of a short-term oncological outcome, mainly the early recurrence disease, 
which has been scarcely investigated in the field of colorectal liver surgery and the effort 
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to analyze numerous factors potentially related to DFS.  Another strength of this study is 
the analysis of a “real-world” population, characterized by an advanced age compared 
with previous study and affected by a multimorbidity. This complex biological 
phenotype is not found in clinical trials where highly selected populations are generally 
enrolled. Moreover, in these series, all patients received surgery for both primary 
colorectal cancer and for liver resection in our center. 
Interestingly, the mean resection margin in our cohort of patients was 1.4 mm ± 1.5 mm, 
and the majority of parenchymal sparing are ≤ 1 mm. These features reflected an 
extreme parenchyma-sparing operative approach, if compared with the contemporary 
literature, and suggested that the possibility of achieving a minimum size of the surgical 
margin strictly depend on the experience of the surgeon and the applied resection 
technique. It is noteworthy that diverse transection techniques may create a margin of 
different character and it has been repeatedly reported that certain transection technique, 
as in the case of CUSA (Cavitron Ultrasound Surgical Aspirator), may distort the margin 
edge by aspirating or ablating a few mm of surrounding hepatic tissue. Consequently, 
pathologic assessment may tend to underestimate margin width and overestimate the 
frequency of R1 resections in such cases. In a recent Cochrane meta-analysis, assessing 
the benefits and risks of the different techniques of parenchymal transection during liver 
resections, clamp-crush technique is advocated as the method of choice in liver 
parenchymal transection in comparisons with CUSA or with radiofrequency dissecting 
sealer (RFDS)[75]. Unfortunately, in our study Kelly clamp liver transection technique 
was used in all the series, not allowing any possible comparison.  
The main limitations of our study include, in the first place, its small size and “single-
centre" nature, that poses the risk of a bias selection. Moreover, during the study period 
that spanned over 5 years, starting from 2014, the center acquired a progressive 
specialization in the field of hepatobilary surgery. The centralization of complex surgical 
procedures has been proposed to optimize short- and long-term outcomes of liver 
surgical procedures and it is strictly correlated with hospital volume. Viganò et al. 
demonstrated that patients managed by HPB referral centers at the first moment of the 
diagnosis have several benefits compared with those initially managed in non-HPB 
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referral hospitals: shorter chemotherapy, better disease control, fewer surgical 
procedures, and, most importantly, longer survival[76]. 
 Finally, the present study enrolled a cohort of patients treated with different 
neoadjuvant or adjuvant chemotherapy plans and the response data for preoperative 
chemotherapy were not routinely recorded at our institution. For this heterogeneity, an 
analysis regarding the effect of chemotherapy in relation to recurrence disease has not 
been performed and it will be investigated in future researches. 
 
2.5 CONCLUSION AND FUTURE DIRECTIONS 
Due to the broadening indication of CRLM resection, the preferred surgical technique 
should be a parenchymal-sparing non-anatomic resection using modern surgical devices 
to keep as much liver parenchyma as possible.  Many studies have attempted to define 
factors predicting survival and non-recurrence after hepatic resection in patients with 
colorectal liver metastases, but there is still debate over which groups of patients benefit 
from surgery. As surgery remains the only curative treatment, a careful patient selection 
and a judicious use of adjuvant therapies prior to and after surgery are crucial to 
continue offering patients with CLM a real chance of a cure. The identification of those 
patients at risk of early recurrence development, failing to benefit from surgery, may 
help select patients to undergo further detailed pre-operative radiological staging of the 
disease. 
Future study will need to consider the tumor margin microenvironment as well as other 
indicators of underlying tumor biology, or stratifying patients according to gene 
mutation status. These kinds of researches might shed light on the creation of new scores 
overwhelming the current models proposed by Fong and colleagues[33] and leading to a 
better selection of patients who could truly benefit from surgery. 
Concluding, since surgery represents only one of the most decisive step of the treatment 
of this complex oncologic disease, a multidisciplinary team becomes a key feature in its 
managing. Each professional figure (oncologist, surgeon, radiologist and pathologist) 
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should demonstrate high expertise and competence in liver metastasis management, as 
the only effective strategy able to guarantee short term and long term oncological and 






















Appendix A. Clinicopathologic characteristics of the 24 patients with recurrence. 
ID 
patient 
Gender Age LN* Onset** Number of 
metastasis 
GP FU status OS Site 
recurrence 
DFS 
1 F 82 + S 1 NA Death 423 Liver, lung 140 
2 F 65 + S 1 NA Death 366 Lung; lymph 
node 
340 
3 F 70 + S 1 NA Death 1056 Peritoneal 370 
4 M 59 + S 1 NA Death 1581 Liver; pelvis 868 
5 M 58 - M 1 NA Recurrence 1781 Liver 298 
6 M 59 + S 2 Pushing Death 1581 Liver; other 780 
7 M 58 - M 2 Mixed Recurrence 1781 Liver 162 
8 M 86 - M 1 Pushing Death 268 Liver 252 
9 F 75 - S 1 Pushing Death 218 Liver 162 
10 F 74 + M 1 Mixed Recurrence 1468 Liver 331 
11 F 68 + S 1 Mixed Death 660 Liver 335 
12 F 38 - S 1 NA Death 879 Lung; brain 153 
13 M 77 + S 1 NA Recurrence 435 Lymph node 252 
14 M 74 + S 1 Pushing Recurrence 249 Liver; lung; 
bones 
98 
15 M 76 + S 1 NA Recurrence 1060 Lung 177 
16 F 76 - S 1 NA Recurrence 1067 Liver 137 
17 M 86 + M 1 Mixed Recurrence 783 Liver 228 
18 F 43 + S 4 NA Recurrence 706 Anastomosis 364 
19 M 79 + M 3 Replacement Death 670 Liver 278 
20 F 55 + S 1 Mixed Recurrence 691 Liver; 
peritoneal 
579 
21 M 74 - S 3 Mixed Recurrence 680 Liver 144 
22 M 53 + S 1 Pushing Recurrence 598 Lung 77 
23 M 65 - S 1 Pushing Recurrence 598 Liver; 
peritoneal 
85 
24 M 55 + S 14 Replacement Death 743 Liver; 
peritoneal 
77 
Abbreviations: *onset: Synchronous or Metachronous; GP: Growth pattern; **LN: lymph node metastasis of the 
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